tirzepatide brand 60mg/3mL (20mg/mL) the dual Zepbound

A significant number of patients with multiple myeloma continue to relapse and become refractory to currently available therapies, representing one of the largest and most challenging unmet needs in the disease, Ester in t Groen, EMEA Therapeutic Area head, Haematology, at Johnson & Johnson, stated in a news release.1 Making teclistamab monotherapy available to patients as early as second line, where it has the potential to meaningfully improve long-term outcomes and change the course of the disease, could bring new hope to patients and their families. To view or add a comment, sign in 7,151 followers

Adjustment was made for sex, age and BMI

15% body weight)

With the arrival of lower manufacturer prices and generic liraglutide, employers may find GLP-1 coverage more financially sustainable going forward